{
  "Cancer Histology Subtype (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1702, 
        1708
      ]
    }, 
    {
      "__agreement__": "FALSE POSITIVE", 
      "__annotator__": "Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2140, 
        2145
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2154, 
        2164
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2443, 
        2449
      ]
    }
  ], 
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1709, 
        1718
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2450, 
        2459
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1525, 
        1548
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1550, 
        1566
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5710, 
        5730
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5732, 
        5740
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1588, 
        1615
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1617, 
        1627
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1638, 
        1642
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2347, 
        2351
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5666, 
        5667
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5688, 
        5689
      ]
    }
  ], 
  "Lymphatic System Location (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5690, 
        5707
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        546, 
        575
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        577, 
        594
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5610, 
        5636
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5638, 
        5656
      ]
    }
  ], 
  "Neoplasm Grade Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Ben,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1765, 
        1766
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Ben,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2507, 
        2508
      ]
    }
  ], 
  "Neoplasm Grade-Score Name (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Ben,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1723, 
        1753
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Ben,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2464, 
        2495
      ]
    }
  ], 
  "Neoplasm Score Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Ben,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1754, 
        1755
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Ben,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2496, 
        2497
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        704, 
        710
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1630, 
        1636
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5668, 
        5674
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1643, 
        1652
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5675, 
        5679
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        675, 
        677
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        959, 
        961
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        962, 
        964
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        1178, 
        1180
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1627, 
        1629
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2343, 
        2345
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        3130, 
        3131
      ]
    }, 
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        4820, 
        4821
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5658, 
        5665
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5680, 
        5687
      ]
    }
  ], 
  "Supplementary Report Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3086, 
        3118
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3120, 
        3129
      ]
    }
  ], 
  "__text": "MSH|^~\\&|LABCORP-CORP|LABCORP^34D0655059^CLIA|Cancer Registry|State|201706010938|State006|ORU^R01|2017060107093839521000|P|2.3.1\nPID|1||^^^^SS^~11111111^^^^PI^|ALTERNATE ID|TEST^PATIENT^A||19500601|M||2054-5^Black or African American^CDC^^^|1234 Test Road^^ALBANY^NY^12201||^^^^^222^1234567|||||||\nORC|RE||111A1111111||||||||||||||||||Ordering Facility Name^^L|2222 W. Test Road^^Test^TX^77025|^^^^^111^1234567||\nOBR|1||111A1111111|^^^111111^Pathology Report^L|||201705301335|||||||20090115||Ordering Provider Name||||||20170530|||F|||||||\n\n\n\n\n\n\nPath report.gross observation\n\nGross description: Received two formalin-filled containers, both labeled with the patient's name: A. In a container labeled \"L breast mass 3 o'clock\", the specimen is  received with a plastic filter, sample loose in container and consists  of multiple portions of tissue and blood which aggregate to 1.5 x 0.5  x 0.2 cm. The specimen is filtered and entirely submitted in cassette  A. B. In a container labeled \"L axilla lymph node\", the specimen consists of  three light yellow-gray, cylindrical-shaped portions of tissue which  range in length from 0.7 cm to 0.8 cm. Entirely submitted in cassette  B. \n Collection date: 7/28/17. Collection time: 8:55 a.m. Total fixation time: 12 hours, up to 24. (DC:cmc88 718300) /FRR\n\n\nPayment procedure\n\nCPT                            .883051, 883052, 883601, 883602, 883603\n\n\nPATHOLOGIST NAME\n\nElectronically signed: Pathologist name, Pathologist\n\n\nDiagnosis ICD code\n\nPathologist provided ICD-10:C50.412\n\n\nPath report.relevant Hx\n\nClinical history: A-3:00, 42MM MASS\n\n\nPath report.final diagnosis\n\nDiagnosis:A. Breast, Left 3 o'clock, 42 mm Mass, Core Needle Biopsies:   Infiltating ductal carcinoma.   -Modified Bloom-Richardson scor 8/9, grade 3/3.    Tubule formation score: 3/3; nuclear grade score:3/3; mitotic    score : 2 (10 mitoses per 10 high-power fields).   -Tumor involves 3 of 3 cores.   -Greatest linear tumor measurement is 16 mm.   -Lymphvascular space invasion: Identified.   -Microcalcifications: Identified.   -Perineural invasion: Not identified.   -Ductal carcinoma in situ: Present, not extensive, solid and     cribriform types, without comedonecrosis, without     microcalcifications.   -Estrogen receptor, progesterone receptor and HER-2/neu status:    Pending; results to be issued by addendum. \n B. \"Left Axilla Lymph Node\" Core Needle Biopsies:   Fibroadipose tissue involved by:   Infiltrating ductal carcinoma.   -Modified Bloom-Richardson score 8/9, grade 3/3.    Tubule score 3/3; nuclear grade score 3/3; mitotic score 2/3    (6 mitoses per 10 high-power fields).   -Lymph node capsule or lymphoid tissue not identified.   -Tumor involves 3 of 3 cores.   -Greatest linear tumor measurement is 8 mm.   -Microcalcifications: Identified.   -Perineural invasion: Not identified.   -Vascular space invasion: Suspicious; to be further assessed by    immunohistochemistry; results to be issued by addendum.   -Ductal carcinoma in situ: Not identified. MRV/07/31/2017 **********************************************************************\n\n\nPath report.supplemental reports\n\nAddendum: A) Receptor studies were performed by immunohistochemistry on sections from block #A1 with the following results: ESTROGEN RECEPTOR (SP1):Positive. 90% strong nuclear positivity. No internal control present. Cold ischemic time unknown. \n PROGESTERONE RECEPTOR (1E2): Positive. 10%, moderate nuclear positivity. No internal control. Cold ischemic time unknown. \n HER-2 (4B5):Equivocal. Weak to moderate complete staining of membrane in greater than 10% of cancer cells, score 2+. \n \n HER-2/neu FISH testing will be performed and results will be issued separately. \n TECHNICAL NOTE: Cold ischemic time is <5 minutes. The scoring criteria for breast biomarkers by immunohistochemstry is based on the current ASCO/CAP guidelines (Hammond et al, Arch Pathol Lab Med 2010: 134(6): 907-922 & Wolff AC et al, Arch Pathol Lab Med 2014: 138(2): 241-256). Deparaffinized sections of formalin fixed tissue (along with appropriate positive controls) are incubated with the above antibody(s). Using the automated Ventana stainer, tissue is incubated with the designated antibody* which is then localized by a non-biotin, dual polymer detection system. The external controls are reviewed for appropriate reactivity and found to be adequate. Results on the target call population are indicated above. These tests have not been validated on decalcified tissue. * This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. \n Part B) Immunohistochemistry for D2-40 (lymphatic marker) is performed in order to assess for lymphatic space invasion. The immunohistochemical stain shows high background stromal and tumor cytoplasmic staining making it difficult to interpret lymphatic space invasion. Hence, this slide is noncontributory and there will be no charge for this stain. The above diagnosis remains unchanged. \n * This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. MRV/08/01/2017 Addendum Electronically Signed by Dermatopatho\n\n\nPath report.site of origin\n\nMaterial submitted: PART A: L BREAST 3:00 PART B: L AXILLA LYMPH NODE\n\n\nPath report.comments\n\nComment:Immunohistochemistry for ER, PR and HER-2/neu will be performed on the left breast 3 o'clock biopsy. \n While part B is designated left axilla lymph node, a lymph node capsule or lymphoid tissue is not identified in the sample received.Total replacement of a lymph node cannot be excluded versus extracapsular extension into soft tissue. \n This case has been reviewed by Dr. Kandalaft who concurs with the above diagnosis. \n \n \n \n * This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research.\n\n\n"
}